Biopharma Partnerships
Working together to advance cancer care.
Advancing novel cancer therapeutics through deep proteomic solutions.
Astrin Biosciences partners with biopharma companies to accelerate precision oncology programs across cancer indications and therapeutic modalities—from research through clinical trials. Our team brings deep expertise in biomarker discovery, drug–diagnostic co-development, companion diagnostics, and commercialization. Astrin delivers cancer detection, classification, and quantification insights through analysis of protein-based signatures across the disease continuum, from early to advanced cancer. Data from Astrin’s studies demonstrate analytically validated performance with strong sensitivity, specificity, and precision.
Add a New Dimension of Insights to Your View of Cancer
While traditional methods have focused on analyzing the genome, we instead investigate the functional units of a cell and the body, known as the proteome. The proteome reveals more of what is happening in real time in the body, enabling deep insights into biology and disease. Astrin’s Certitude is a liquid biopsy-based deep proteomic platform for early cancer detection, with the aim to find cancer at the earliest stages using only 100 µL of plasma. This platform enables detection of thousands of proteins with minimal sample volume allowing our partners to not only acquire robust proteomic datasets for investigation but to also save valuable material for other studies.
Reach Out
Partner with Astrin for your women’s and men’s health testing needs across protein-based biomarker discovery and diagnostic tests and clinical studies to amplify and fast-track your efforts to bring impactful clinical solutions.
Contact us by filling out the following form, and our team will get in touch: